Zymeworks Inc. (ZYME) stock

ZYMENasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30117% above fair value

$26.24−0.23 (-0.87%)

Close on Nov 13, 2026Market cap $1.86BP/E 50.5Yield –

Zymeworks price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Zymeworks's price to book ratio was 25.8× on Nov 11, 2026, against 6.3× a year earlier. Over the last 5 years it ranged from 1.0× to 26.1×, with a median of 2.2×.

Price to Book Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	25.8×	+19.6
2025	Dec 31, 2025	6.2×	+3.4
2024	Dec 31, 2024	2.8×	+1.1
2023	Dec 29, 2023	1.7×	−1.0
2022	Dec 30, 2022	2.7×	+0.7
2021	Dec 31, 2021	2.0×	–

Where these numbers come from

Parsed from the XBRL in Zymeworks's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ZYME.

Compare: ZYME vs XNCR · ZYME vs ANAB · ZYME vs IDYA · ZYME vs NUVB · ZYME vs PBYI

Revenue growth97.8% · median 23.3%

Operating margin16.6% · median -61.2%

Net margin16.3% · median -58.8%

Company	Revenue	Growth
ZYME	$265.97M	+97.8%
IDYA	$234.13M	–
PBYI	$231.83M	+9.4%
NUVB	$201.73M	+654.2%
XNCR	$200.49M	+33.5%
ANAB	$191.57M	+13.0%

Company

Next earnings (est.): Mar 1, 2027, before open
Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 264
Held by institutions: 98.1%
Auditor: KPMG LLP
SEC CIK: 1937653

Advertisement
300 × 250

See a number that looks wrong?